The effect of self-monitoring of blood glucose (SMBG) on glycemic control with regard to non-insulintreated Type 2 diabetes mellitus (NIT-Type 2 DM) is still a controversial topic. Against this backdrop, we sought to compare the effect of a continuous short-term SMBG schema with as-usual treatment, based on changes in oral antidiabetic treatment in patients with poorly controlled Type 2 DM. We reviewed 492 NIT-Type 2 DM record charts, selecting 27 patients, with poor glycemic control, who were thought to self-monitor their blood glucose levels (SMBG group). We then compared them with 27 patients treated with modifying drugs or diets to achieve and maintain the glycemic target (Control Group). Haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) were evaluated at baseline, after 3 and 6 months. HbA1c values decreased after 3 and 6 months in the SMBG group (P < 0.001 on both occasions) and in the control group (P < 0.05 and P < 0.01, respectively), but without a significant difference between the two groups when compared at the same time. The FPG progressively decreased in both groups, reaching a significant difference in the SMBG group after 3 months and in the control group after 6 months, and without a significant difference between the two groups. The SMBG schema used in our study could be adopted for target groups before proceeding to the next therapeutic enhancement drug step, representing a useful tool that can help diabetic patients in raising awareness of and treating their disease.

Effect of a standard schema of self-monitoring blood glucose in patients with poorly controlled, non-insulin-treated type 2 diabetes mellitus: A controlled longitudinal study / Madeo, B.; Diazzi, C.; Granata, A. R. M.; Ghoch, M. E.; Greco, C.; Romano, S.; Scaltriti, S.; Rochira, V.. - In: JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY. - ISSN 2561-8741. - 27:2(2020), pp. e1-e11. [10.15586/jptcp.v27iSP2.680]

Effect of a standard schema of self-monitoring blood glucose in patients with poorly controlled, non-insulin-treated type 2 diabetes mellitus: A controlled longitudinal study

Madeo B.
Conceptualization
;
Diazzi C.
Methodology
;
Greco C.
Writing – Original Draft Preparation
;
Romano S.
Data Curation
;
Scaltriti S.
Formal Analysis
;
Rochira V.
Writing – Review & Editing
2020

Abstract

The effect of self-monitoring of blood glucose (SMBG) on glycemic control with regard to non-insulintreated Type 2 diabetes mellitus (NIT-Type 2 DM) is still a controversial topic. Against this backdrop, we sought to compare the effect of a continuous short-term SMBG schema with as-usual treatment, based on changes in oral antidiabetic treatment in patients with poorly controlled Type 2 DM. We reviewed 492 NIT-Type 2 DM record charts, selecting 27 patients, with poor glycemic control, who were thought to self-monitor their blood glucose levels (SMBG group). We then compared them with 27 patients treated with modifying drugs or diets to achieve and maintain the glycemic target (Control Group). Haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) were evaluated at baseline, after 3 and 6 months. HbA1c values decreased after 3 and 6 months in the SMBG group (P < 0.001 on both occasions) and in the control group (P < 0.05 and P < 0.01, respectively), but without a significant difference between the two groups when compared at the same time. The FPG progressively decreased in both groups, reaching a significant difference in the SMBG group after 3 months and in the control group after 6 months, and without a significant difference between the two groups. The SMBG schema used in our study could be adopted for target groups before proceeding to the next therapeutic enhancement drug step, representing a useful tool that can help diabetic patients in raising awareness of and treating their disease.
2-set-2020
27
2
e1
e11
Effect of a standard schema of self-monitoring blood glucose in patients with poorly controlled, non-insulin-treated type 2 diabetes mellitus: A controlled longitudinal study / Madeo, B.; Diazzi, C.; Granata, A. R. M.; Ghoch, M. E.; Greco, C.; Romano, S.; Scaltriti, S.; Rochira, V.. - In: JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY. - ISSN 2561-8741. - 27:2(2020), pp. e1-e11. [10.15586/jptcp.v27iSP2.680]
Madeo, B.; Diazzi, C.; Granata, A. R. M.; Ghoch, M. E.; Greco, C.; Romano, S.; Scaltriti, S.; Rochira, V.
File in questo prodotto:
File Dimensione Formato  
0096_Madeo_et_al_J_Population_Therapeutics_&_Clinical_Pharmacology_2020.pdf

accesso aperto

Descrizione: Full text of the published article
Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 738.88 kB
Formato Adobe PDF
738.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1215163
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact